Spots Global Cancer Trial Database for A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Official Title: Phase II Trial of a Bivalent Vaccine With the Immunological Adjuvant OPT-821 (QS-21), in Combination With Randomization of Oral β-glucan, for High-Risk Neuroblastoma
Study ID: NCT06057948
Study Description
Brief Summary: The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.
Detailed Description:
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Consent Only), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States
Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack, New York, United States
Memorial Sloan Kettering Westchester (Consent only), Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Memorial Sloan Kettering Nassau (Consent Only), Uniondale, New York, United States
Contact Details
Name: Brian Kushner, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
